Food

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Thursday, October 21, 2021 - 9:00am

Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

Key Points: 
  • Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.
  • This technology has the potential to widen the therapeutic index of an ADC and to make our Nectin-4 ADC a best-in-class.
  • Pursuant to the agreement, Mablink Bioscience is entitled to receive milestone and royalty payments, based on the development of the Nectin-4 ADC.
  • Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers.

The Rat Pack: Former Top Five Cities Remain Leaders on Orkin's 2021 Rattiest Cities List

Thursday, October 21, 2021 - 5:01am

Thanks to their human neighbors being back in houses and apartments, food and water sources have been replenished for rodents.

Key Points: 
  • Thanks to their human neighbors being back in houses and apartments, food and water sources have been replenished for rodents.
  • As the U.S. population faces a "new normal," managing an influx in rodent populations and activity in major cities across the country should remain a top concern.
  • With more time spent around the home than ever before, residents should pay extra attention to the attractants that entice rats and mice .
  • The good news is, while a surging world-wide pandemic feels largely out of control, a rat infestation is manageable and preventable.

The Vita Coco Company Announces Pricing of Initial Public Offering

Thursday, October 21, 2021 - 4:15am

The Vita Coco Company, Inc. (NASDAQ:COCO), a leading platform of high-growth better-for-you brands formerly known as All Market Inc., today announced the pricing of its initial public offering of 11,500,000 shares of common stock, of which 2,500,000 are being offered by The Vita Coco Company and 9,000,000 are being offered by certain selling stockholders at a price to the public of $15.00 per share.

Key Points: 
  • The Vita Coco Company, Inc. (NASDAQ:COCO), a leading platform of high-growth better-for-you brands formerly known as All Market Inc., today announced the pricing of its initial public offering of 11,500,000 shares of common stock, of which 2,500,000 are being offered by The Vita Coco Company and 9,000,000 are being offered by certain selling stockholders at a price to the public of $15.00 per share.
  • The initial public offering is expected to close on October 25, 2021, subject to the satisfaction of customary closing conditions.
  • The Vita Coco Company was co-founded in 2004 by co-CEO Michael Kirban and Ira Liran.
  • Pioneers in the functional beverage category, The Vita Coco Companys brands include the leading coconut water, Vita Coco; clean energy drink Runa; sustainable enhanced water, Ever & Ever; and protein-infused water, PWR LIFT.

Catania Media Consultants LLC Named to TAMPA Magazines' 2021 Best of the City List

Thursday, October 21, 2021 - 2:00am

TAMPA, Fla., Oct. 20, 2021 /PRNewswire/ -- Catania Media Consultants LLC was named a Best Advertising Agency on TAMPA Magazines' 2021 Best of the City list.

Key Points: 
  • TAMPA, Fla., Oct. 20, 2021 /PRNewswire/ -- Catania Media Consultants LLC was named a Best Advertising Agency on TAMPA Magazines' 2021 Best of the City list.
  • For the first time, the list was published in TAMPA Magazine, South Tampa Magazine, Tampa Downtown Magazine and Tampa Digest Magazine.
  • The full 2021 Best of Tampa list is now available in the October 2021 issue of TAMPA Magazine, South Tampa Magazine, Tampa Downtown Magazine and Tampa Digest Magazine.
  • TAMPA Magazines is the parent company of TAMPA Magazine, Tampa Downtown Magazine, Tampa Digest Magazine and South Tampa Magazine.

Greenberg Traurig Advises Hugo Technologies in Sale of Its Food and Grocery Delivery Business to Delivery Hero SE

Thursday, October 21, 2021 - 1:50am

MIAMI, Oct. 20, 2021 /PRNewswire-PRWeb/ -- A team of attorneys from global law firm Greenberg Traurig, LLP represented Hugo Technologies, the owner of the popular Hugo App, in negotiating the sale of its food and grocery delivery business to Delivery Hero SE, the world's leading local delivery platform.

Key Points: 
  • MIAMI, Oct. 20, 2021 /PRNewswire-PRWeb/ -- A team of attorneys from global law firm Greenberg Traurig, LLP represented Hugo Technologies, the owner of the popular Hugo App, in negotiating the sale of its food and grocery delivery business to Delivery Hero SE, the world's leading local delivery platform.
  • The transaction, which is expected to close in the first quarter of 2022, will expand Delivery Hero's business in Latin America and the Caribbean.
  • It operates as a multi-category marketplace offering on-demand delivery for restaurants, grocery stores, and pharmacies, plus a variety of digital payment services.
  • About Greenberg Traurig: Greenberg Traurig, LLP (GT) has approximately 2300 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline – SAVA

Thursday, October 21, 2021 - 12:34am

To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Cassava is an Austin-based clinical stage biotechnology company engaged in the development of drugs for neurodegenerative diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

Thursday, October 21, 2021 - 12:24am

NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ:RVNC).

Key Points: 
  • NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ:RVNC).
  • Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext.
  • The investigation concerns whether Revance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDL

Thursday, October 21, 2021 - 12:17am

NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc (Avadel or the Company) (NASDAQ:AVDL).

Key Points: 
  • NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc (Avadel or the Company) (NASDAQ:AVDL).
  • Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext.
  • The investigation concerns whether Avadel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI

Thursday, October 21, 2021 - 12:11am

NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (Spectrum or the Company) (NASDAQ: SPPI) and certain of its officers.

Key Points: 
  • NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (Spectrum or the Company) (NASDAQ: SPPI) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Thrive Acquisition Corporation Announces Pricing of $150 Million Initial Public Offering

Thursday, October 21, 2021 - 12:52am

Thrive Acquisition Corporation (the Company) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit.

Key Points: 
  • Thrive Acquisition Corporation (the Company) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit.
  • Thrive Acquisition Corporation, led by CEO Charles Jobson, is a special purpose acquisition company formed with the purpose of entering into a business combination with one or more businesses.
  • The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units at the initial public offering price to cover over-allotments, if any.
  • This press release contains statements that constitute forward-looking statements, including with respect to the initial public offering and search for an initial business combination.